ÉTUDE PRODIGE 79-GERCOR-DAVIRIPAC - Abandonné
Title
A multicenter, randomized, open-label, non-comparative 2-stage clinical trial to evaluate the efficacy of DAV132 to prevent dose-limiting irinotecan-induced diarrhea in patients with advanced pancreatic adenocarcinoma treated with FOLFIRI.3 as third-line therapy
Coordonateur
NEUZILLET C
Co-Coordonateur
CHANEZ B
Promoteur
GERCOR
Localisation
Cancer du Pancréas
Phase
IIR
NOMBRE DE PATIENTS ATTENDU
Statut
Abandonné
CONTACT
c-dumasbonnetain@unicancer.fr